SLC5A2 and Hypomagnesemia: While proposed mechanisms for this magnesium-sparing effect include improved insulin sensitivity and enhanced renal reabsorption via transient receptor potential Melastatin 6 (TRPM6) channels [3], the efficacy of SGLT2 inhibitors in nondiabetic patients with hypomagnesemia remains underexplored.